down arrow

ImmunoGen, Inc.

  • Market Cap: Mid Cap
  • Industry: Biotechnology
  • ISIN: US45253H1014
USD
31.23
0.00 (0.00%)

Feb 13

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

3.6131.25
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2023)

FII

17.84%

Held by 138 FIIs

DII

41.73%

Held by 66 DIIs

Promoter

5.67%

How big is ImmunoGen, Inc.?

22-Jun-2025

As of September 2023, ImmunoGen, Inc. has an unavailable market capitalization. The company reported net sales of $287.61 million and a net loss of $73.52 million for the latest four quarters, with shareholder's funds of $155.83 million and total assets of $348.94 million as of December 2022.

As of September 2023, ImmunoGen, Inc. has a market capitalization value that is not available, making it difficult to categorize its market cap type.<BR><BR>As of September 2023, the company reported net sales of 287.61 million for the latest four quarters. During the same period, the consolidated net profit was a loss of 73.52 million.<BR><BR>As of December 2022, the reporting period for the balance sheet shows shareholder's funds of 155.83 million and total assets of 348.94 million.

Read More

Who are in the management team of ImmunoGen, Inc.?

22-Jun-2025

As of March 2022, the management team of ImmunoGen, Inc. includes Mr. Stephen McCluski (Independent Chairman), Mr. Mark Enyedy (President and CEO), and several independent directors: Mr. Stuart Arbuckle, Dr. Mark Goldberg, Mr. Dean Mitchell, Ms. Kristine Peterson, and Mr. Richard Wallace. They oversee the company's strategic direction and operations.

As of March 2022, the management team of ImmunoGen, Inc. includes the following individuals:<BR><BR>- Mr. Stephen McCluski, Independent Chairman of the Board<BR>- Mr. Mark Enyedy, President, Chief Executive Officer, Director<BR>- Mr. Stuart Arbuckle, Independent Director<BR>- Dr. Mark Goldberg, Independent Director<BR>- Mr. Dean Mitchell, Independent Director<BR>- Ms. Kristine Peterson, Independent Director<BR>- Mr. Richard Wallace, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD Million (Mid Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.90

stock-summary
Return on Equity

-13.09%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
113 Million
(Quarterly Results - Sep 2023)
Net Profit:
31 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
111.87%
0%
111.87%
6 Months
117.33%
0%
117.33%
1 Year
617.93%
0%
617.93%
2 Years
442.19%
0%
442.19%
3 Years
196.58%
0%
196.58%
4 Years
482.65%
0%
482.65%
5 Years
471.98%
0%
471.98%

ImmunoGen, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
29.33%
EBIT Growth (5y)
6.49%
EBIT to Interest (avg)
-11.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.54
Tax Ratio
1.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
6.27
EV to EBITDA
6.41
EV to Capital Employed
-8.60
EV to Sales
-1.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-13.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bearish
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 76 Schemes (34.75%)

Foreign Institutions

Held by 138 Foreign Institutions (17.84%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 636.36% vs 67.39% in Sep 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 139.46% vs -108.58% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "113.40",
          "val2": "15.40",
          "chgp": "636.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "26.40",
          "val2": "-77.00",
          "chgp": "134.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "0.90",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.70",
          "val2": "-77.80",
          "chgp": "139.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "228.80%",
          "val2": "-5,036.00%",
          "chgp": "526.48%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 55.65% vs -47.17% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -60.01% vs -213.74% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "108.80",
          "val2": "69.90",
          "chgp": "55.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-219.10",
          "val2": "-120.10",
          "chgp": "-82.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.20",
          "val2": "13.10",
          "chgp": "-67.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-222.90",
          "val2": "-139.30",
          "chgp": "-60.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,030.60%",
          "val2": "-1,748.00%",
          "chgp": "-28.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - YoYstock-summary
Sep'23
Sep'22
Change(%)
Net Sales
113.40
15.40
636.36%
Operating Profit (PBDIT) excl Other Income
26.40
-77.00
134.29%
Interest
3.60
0.90
300.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
30.70
-77.80
139.46%
Operating Profit Margin (Excl OI)
228.80%
-5,036.00%
526.48%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2023 is 636.36% vs 67.39% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 139.46% vs -108.58% in Sep 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
108.80
69.90
55.65%
Operating Profit (PBDIT) excl Other Income
-219.10
-120.10
-82.43%
Interest
4.20
13.10
-67.94%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-222.90
-139.30
-60.01%
Operating Profit Margin (Excl OI)
-2,030.60%
-1,748.00%
-28.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 55.65% vs -47.17% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -60.01% vs -213.74% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About ImmunoGen, Inc. stock-summary
stock-summary
ImmunoGen, Inc.
Biotechnology
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
Company Coordinates stock-summary
Company Details
84 State St , BOSTON MA : 02109-2202
stock-summary
Tel: 1 781 8950600
stock-summary
http://www.immunogen.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."